Is tremfya safe?

Is Tremfya linked to higher infection risk?

Tremfya (guselkumab) belongs to a class of drugs that suppress parts of the immune system, so patients are at elevated risk of serious infections. Clinical trials reported serious infections in 1.7% of treated patients versus 1.0% in the placebo group. Serious bacterial, viral, and fungal infections—sometimes leading to hospitalization—have occurred during treatment. Doctors screen for latent tuberculosis before prescribing and continue monitoring for active infections throughout use.

Does Tremfya carry cancer concerns?

The same immune-modulating mechanism raises questions about cancer risk. Clinical data do not yet show a clear statistical increase in malignancies, but long-term studies continue to track this possibility because immunosuppression generally heightens cancer probability. Patients are advised to watch for signs such as unexplained weight loss or persistent lumps and to report them promptly.

Can Tremfya affect liver function?

Tremfya has been evaluated in liver-safety studies. Liver enzyme elevations occurred in a small percentage of patients, but most cases waren reversible upon discontinuation. Doctors routinely check liver tests before starting and during treatment.

What happens if someone becomes pregnant while on Tremfya?

Animal studies showed developmental harm at doses far above human levels. No adequate human data exist. Therefore doctors usually advise stopping Tremfya before conception and using effective contraception during treatment plus five months afterward.